 SAN FRANCISCO, March 25, 2020 GLOBE NEWSWIRE -- 89bio, Inc. ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Steven Altschuler, M.D., as chairman of its board of directors. We are very pleased to welcome Steven as chairman of 89bios board of directors, said Greg Grunberg, chair of the nominating and corporate governance committee of 89bios board of directors. 